Pathogenesis of psoriasis in the “omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis
Bogusław Nedoszytko,Aneta Szczerkowska-Dobosz,Marta Stawczyk-Macieja,Agnieszka Owczarczyk-Saczonek,Adam Reich,Aleksandra Batycka-Baran,Rafał Czajkowski,Magdalena Górecka-Sokołowska,Anna Janaszak-Jasiecka,Leszek Kalinowski,Dorota Krasowska,Dorota Purzycka-Bohdan,Adrianna Radulska,Edyta Reszka,Dominik Samotij,Marta Sobalska-Kwapis,Andrzej Słominski,Radomir Słominski,Dominik Strapagiel,Michał Żmijewski,Joanna Bartosińska,Iwona Dobrucki,Lawrence Dobrucki,Justyna Szczęch,Roman Nowicki
DOI: https://doi.org/10.5114/ada.2020.96243
2020-01-01
Advances in Dermatology and Allergology
Abstract:Psoriasis is a multifactorial disease in which genetic, environmental and epigenetic factors regulating gene expression play a key role. In the "genomic era", genome-wide association studies together with target genotyping platforms performed in different ethnic populations have found more than 50 genetic susceptible markers associated with the risk of psoriasis which have been identified so far. Up till now, the strongest association with the risk of the disease has been proved for HLA-C*06 gene. The majority of other psoriasis risk SNPs are situated near the genes encoding molecules involved in adaptive and innate immunity, and skin barrier function. Many contemporary studies indicate that the epigenetic changes: histone modification, promoter methylations, long non-coding and micro-RNA hyperexpression are considered as factors contributing to psoriasis pathogenesis as they regulate abnormal keratinocyte differentiation and proliferation, aberrant keratinocytes - inflammatory cells communication, neoangiogenesis and chronic inflammation. The circulating miRNAs detected in the blood may become specific markers in the diagnosis, prognosis and response to the treatment of the disease. The inhibition of expression in selected miRNAs may be a new promising therapy option for patients with psoriasis.